Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics...
Cancer
BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data demonstrating...
Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Study site initiations in the United States for a randomized Phase 2/3 study of CTX-009 with paclitaxel in patients with Biliary...
Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022
Menlo Park, California, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today...
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering...
Morphic Announces Participation in 2022 Jefferies London Healthcare Conference
WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of...
MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs
Paper published in the November 2022 issue of Podiatry Management(Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM,...
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022
Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients...
AUM Biosciences to Participate in BioCentury-BayHelix East-West BioPharma Summit
SINGAPORE and BETHESDA, Md., Nov. 04, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing...
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
ALG-055009, a THR-β agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a...
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and...
ORYZON to Give Updates on Corporate Progress in November
Kabuki Syndrome Foundation Annual Conference11th Drug Discovery Strategic SummitInv€$tival Showcase LSX Leaders 2022Jefferies London Healthcare Conference 2022MADRID, Spain and BOSTON,...
Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference
Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference...
CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022
NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and...
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
--Poster presentation to showcase NGM Bio’s in vitro and in vivo research supporting development of NGM936, a ILT3 x CD3...
Rain Therapeutics Announces $50 Million Registered Offering of Common Stock
NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision...
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject...
Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)
- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression...
Todos Medical Announces BioFuture™ NYC 2022 Presentation
New York, NY, and Tel Aviv, ISRAEL, Nov. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB:...
Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies...